Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.

Summary

The purpose of this study is to estimate the control rate (CR,PR,SD) of docetaxel and irinotecan (DI) combination chemotherapy for recurrent or refractory bone and soft tissue sarcomas.Al so, this study is to evaluate the toxicity profile of Docetaxel and Irinotecan (DI) combination chemotherapy.

Timeline

Start

2008-04

Primary completion

2014-09

Completion

2014-12

Publications

• Yoon JH, Kwon MM, Park HJ, Park SY, Lim KY, Joo J, Park BK. A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors. BMC Cancer. 2014 Aug 28;14:622. doi: 10.1186/1471-2407-14-622.

Drugs

Indications